Parabilis Medicines is a clinical-stage biopharmaceutical company developing peptide-based drugs designed to reach targets long considered undruggable. Its Helicon platform aims to create tunable therapeutics, with an initial focus that includes oncology and other serious diseases. With little commercial revenue, the company is driven by research, clinical development, and its proprietary modality rather than marketed products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -48.1 | — |
| Q1 2026 | 0 | — | -70.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Enphase Energy, Inc. (ENPH), Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. (OMAB), First Financial Bankshares, Inc. (FFIN), Dyne Therapeutics, Inc. (DYN), LifeStance Health Group, Inc. (LFST), Gentex Corporation (GNTX)